Toshiharu Matsushima
Overview
Explore the profile of Toshiharu Matsushima including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
87
Citations
746
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yamamoto Y, Watanabe A, Goto H, Matsushima T, Abe S, Aoki N, et al.
J Infect Chemother
. 2012 May;
18(4):544-51.
PMID: 22618270
A survey on adult community-acquired pneumonia was conducted jointly by multiple centers nationwide to verify the Japanese Respiratory Society Guidelines for the Management of Community-Acquired Pneumonia in Adults (JRS2005). The...
2.
Watanabe A, Goto H, Kohno S, Matsushima T, Abe S, Aoki N, et al.
Respir Investig
. 2012 May;
50(1):23-32.
PMID: 22554856
Introduction: The Japanese Respiratory Society Guidelines for the Management of Community-Acquired Pneumonia (CAP) in Adults (JRS 2005) was published as a revision of the Basic Concept for the Management of...
3.
Watanabe A, Goto H, Kohno S, Matsushima T, Abe S, Aoki N, et al.
Respir Investig
. 2012 May;
50(1):14-22.
PMID: 22554855
Introduction: The Japanese Respiratory Society Guidelines for the Management of Community-Acquired Pneumonia (CAP) in Adults (JRS 2005) were published to revise the Basic Concept for the Management of CAP in...
4.
Yoshida K, Okimoto N, Kishimoto M, Fukano H, Hara H, Yoneyama H, et al.
J Infect Chemother
. 2011 Aug;
17(5):678-85.
PMID: 21847518
Moxifloxacin is a respiratory quinolone that is expected to be useful for treating community-acquired bacterial pneumonia, but few clinical studies and not a detailed evaluation of its pharmacokinetics have been...
5.
Kobashi Y, Mouri K, Miyashita N, Okimoto N, Matsushima T, Kageoka T, et al.
Scand J Infect Dis
. 2009 Nov;
41(11-12):841-6.
PMID: 19922066
We evaluated the usefulness of the QuantiFERON TB-2G (QFT-2G) test and the tuberculin skin test (TST) in patients with active tuberculosis (TB) disease stratified by age in 10-year increments. Although...
6.
Niki Y, Yoshida K, Miyashita N, Oka M, Hara H, Kishimoto M, et al.
J Infect Chemother
. 2008 Aug;
14(4):296-304.
PMID: 18709533
The efficacy and safety of gatifloxacin (GFLX) was evaluated for elderly patients with respiratory infections. Each patient received one-half (100 mg b.i.d.) or one-quarter (100 mg q.d.) of the conventional...
7.
Kobashi Y, Mouri K, Yagi S, Obase Y, Miyashita N, Okimoto N, et al.
Scand J Infect Dis
. 2008 Jul;
40(8):629-34.
PMID: 18642159
We compared the usefulness of TST, QFT-TB and T-SPOT.TB for the identification of patients with active tuberculosis (TB) disease and investigated transitional change in both tests during anti-tuberculous treatment. The...
8.
Watanabe A, Yanagihara K, Kohno S, Matsushima T
Intern Med
. 2008 Feb;
47(4):245-54.
PMID: 18277024
Objective: The aim of this study was to investigate the pathophysiology of hospital-acquired pneumonia (HAP) and the clinical efficacy of its first-line treatment and to examine the validity of "the...
9.
Kobashi Y, Mouri K, Yagi S, Obase Y, Miyashita N, Okimoto N, et al.
Chest
. 2008 Feb;
133(5):1196-202.
PMID: 18263689
Objective: To evaluate the response to the QuantiFERON-TB-2 Gold (QFT-2G) test (Cellestis Ltd; Carnegie, VIC, Australia) in elderly patients with active tuberculosis (TB) to determine whether the QFT-2G test might...
10.
Clinical features of immunocompromised and nonimmunocompromised patients with pulmonary tuberculosis
Kobashi Y, Mouri K, Yagi S, Obase Y, Miyashita N, Okimoto N, et al.
J Infect Chemother
. 2007 Dec;
13(6):405-10.
PMID: 18095090
Although patients with risk factors for tuberculosis have increased with the increased use of immunosuppressive therapy, there have been few reports about differences in clinical findings between immunocompromised patients and...